AME Logo
AT

Alfredo Tagarro

PhD, MD

Hospital Universitario Infanta Sofía / Instituto de Investigación Hospital 12 de Octubre / Universidad Europea de Madrid

Spain

Biography

Dr. Alfredo Tagarro has been a physician since 1999, a Doctor of Medicine since 2007, and has been a specialist in Pediatrics and a Clinical Researcher since 2004. He has always worked as a clinician in hospitals of the public network, in Pediatric Intensive Care Units and, since 2008, in clinics and emergencies, with a special interest in Infectious Diseases and Rheumatology.

Since 2008, Dr. Tagarro has been working at the Hospital Infanta Sofía, where he has been in charge of Infectious Diseases. He is an accredited full professor of Pediatrics at the European University of Madrid, where he teaches the subject of Pediatrics (5th year) and has supervised several TFGs and three doctoral theses.

Since 2016, he has been part of the Instituto de Investigación 12 de Octubre (Research Institute I+12) as a clinical researcher in the field of HIV. He has led national projects on respiratory infections and COVID-19, and has joined Horizon Europe and EDCTP large projects on HIV, global health, and respiratory diseases funded by EDCTP and Horizon Europe, coordinated both from I+12 and from the Pediatric European Network for the Treatment of Pediatric AIDS (PENTA) as a researcher; for instance, EMPIRICAL, ORCHESTRA, SUPPORT, VERDI, EPIICAL, and ENABLE. He is involved in several research networks and research groups, including PENTA, where he co-leads the Respiratory Group.

Dr. Tagarro serves as an expert for the WHO Child Health Research Prioritization Exercise for the WHO’s Department of Maternal, Newborn, Child and Adolescent Health and Ageing (MCA) and the Research for Health Department (RFH). Along with all health workers in Spain fighting COVID-19, he received the Premio Príncipe de Asturias de la Concordia in 2020.

RELATED COURSES

CME Series | Advances in Clinical Pharmacology of Infectious Diseases
HIV
HIV
NTD
RSV
Tuberculosis
Viral Hepatitis and Liver Disease
60 min
Steve Taylor, Alfredo Tagarro, David L. Thomas

CME Series | Advances in Clinical Pharmacology of Infectious Diseases

This module offers a focused overview of optimal antiviral therapy - HIV PEP, monoclonal antibodies in pediatric infectious diseases, and future directions in HCV. Topics include drug–drug interactions, pharmacokinetics and pharmacodynamics, dosing in under-represented populations, post-marketing safety, and regulatory considerations.

What Will Set You Apart?​

After following this educational series, participants will be able to:

  • Summarize key guidelines and challenges in HIV PEP
  • Describe the role of monoclonal antibodies in pediatric infectious diseases
  • Outline emerging treatment directions for HCV

Is This Program for You?

This program is designed for clinical pharmacologists, pharmacists, clinicians, researchers, postgraduate students, and others engaged in the clinical pharmacology of antiviral therapy.

What Will You Cover in This Module?

  • HIV PEP in Clinical Practice
  • Monoclonal Antibodies in Pediatric Infectious Diseases
  • What Is Next for HCV?